Roth MKM raised the firm’s price target on Zimmer Biomet to $129 from $120 and keeps a Neutral rating on the shares. The firm is updating its model after the company’s Q4 earnings beat while citing its higher confidence in 2024 estimates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet receives FDA clearance for ROSA Shoulder System
- BTIG medical technology analyst to hold analyst/industry conference call
- Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2024
- Zimmer Biomet signs Global Health Equity Network’s Zero Health Gaps Pledge
- Zimmer Biomet price target raised to $130 from $120 at Barclays
